Arthritis News and Research

Latest Arthritis News and Research

Study confirms impact of febrile neutropenia on chemotherapy delivery in NHL

Data presented at the 15th European Hematology Association (EHA) congress in Barcelona, highlights the impact of febrile neutropenia (FN) on chemotherapy delivery in non-Hodgkin lymphoma (NHL) patients. The IMPACT NHL study showed that unplanned hospitalisations, delays in chemotherapy and reductions of chemotherapy dose leading to suboptimal relative dose intensity (RDI) of chemotherapy were more frequent in patients who experienced FN than those who did not.

14 Jun 2010

Chiasma successfully completes Phase I clinical study of Octreolin

Chiasma, Inc., a privately held biopharma company, announced that it has successfully completed a Phase I clinical study evaluating the safety and pharmacokinetics (PK) of its proprietary product Octreolin, which contains the active ingredient octreotide actetate and is administered orally

14 Jun 2010

Emerging science of epigenetics offers new insights at crossroads of genes and the environment: Article

An emerging arm of molecular biology is introducing a new interpretation of traditional concepts of human disease, explains an article published today in Nature. According to author Dr. Arturas Petronis at the Centre for Addiction and Mental Health, the emerging science of epigenetics is offering new insights at the crossroads of genes and the environment, or nature and nurture. Dr. Petronis is head of the Krembil Family Epigenetics Laboratory at CAMH and an international expert in the field.

11 Jun 2010

2010 GAPS sheds light on the painful reality of what life is like for gout patients

The 2010 Gout Attitudes Patient Survey, a new study of Americans with gout, released by Men's Health Network, sheds light on the painful reality of what life is like for the approximately five million Americans who live with this condition. Of those surveyed, 69 percent described the pain of a gout attack as "miserable," yet a quarter of gout patients feel that those without gout perceive them as overreacting to attacks, and 67 percent feel as though others do not take the condition seriously.

11 Jun 2010

Baylor Institute of Immunology Research receives nearly $35M as grants in 2009

Even in an economy that's proved devastating to charitable giving and government grants, the Baylor Institute of Immunology Research (BIIR), a component of Baylor Research Institute (BRI), has managed to buck the trend: BIIR received grants totaling nearly $35 million in 2009.

10 Jun 2010

Human Genome Sciences submits BLA for BENLYSTA to FDA

Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval to market BENLYSTA® (belimumab) for the treatment of systemic lupus erythematosus (SLE).

10 Jun 2010

Preclinical data of VB-201 to be presented at EULAR Annual European Congress of Rheumatology

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of preclinical data from the company's lead program, VB-201, at the European League Against Rheumatism Annual European Congress of Rheumatology.

10 Jun 2010

DermaGenoma releases CelluliteDX Genetic Test for women

As summer swimsuit season heats up, women around the world will inspect their looks in the mirror. A majority of them will see cellulite - at some point - but a new genetic test may be able to help them avoid cellulite before anyone notices.

10 Jun 2010

Therapies for female sexual dysfunction

Many women experience problems in the bedroom at one time or another. Female sexual dysfunction is not uncommon and although some women and healthcare providers have difficulty discussing it, it has been recognized by the medical community for decades. In fact, for the last twenty years, it has been listed in the Diagnostic and Statistical Manual of Mental Disorders, a manual published by the American Psychiatric Association, used to classify and diagnose psychological disorders.

10 Jun 2010

Positive initial results from Nektar Therapeutics' NKTR-102 Phase 2 study for metastatic breast cancer

Nektar Therapeutics today announced positive preliminary initial results from a two-stage Phase 2 clinical study evaluating single-agent NKTR-102 in women with advanced/metastatic breast cancer patients who have received a prior taxane. The increased use of taxanes in breast cancer often renders tumors resistant to these drugs by the time the disease recurs, thereby underscoring the urgent need for new treatment options with novel mechanisms of action for metastatic disease.

10 Jun 2010

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

Regeneron Pharmaceuticals, Inc. announced that a Phase 3 study in gout patients initiating allopurinol therapy to lower their uric acid levels showed that ARCALYST (rilonacept), also known as IL-1 Trap, prevented gout attacks, as measured by the primary endpoint of the number of gout flares per patient over the 16 week treatment period.

9 Jun 2010

Update on Phase II clinical study of CH-4051 in rheumatoid arthritis

Chelsea Therapeutics International, Ltd. announced that during a teleconference yesterday, the U.S. Food and Drug Administration requested that the company delay the initiation of its proposed Phase II clinical study of CH-4051 in rheumatoid arthritis and indicated that the agency is requesting additional detail from the preclinical studies previously submitted as part of the company's investigational new drug application.

9 Jun 2010

Some commonly used drugs cause bone loss: New research

New research helps to explain why some commonly used drugs come with a serious downside: They up your odds of breaking a bone. The drugs in question, glucocorticoids (e.g. cortisone and prednisone) and the insulin sensitizer rosiglitazone work through entirely different mechanisms as therapies for inflammatory diseases and diabetes respectively, and two studies in the June issue of Cell Metabolism now show that they lead to bone loss in different ways too.

9 Jun 2010

Biogen, Elan launch My MS Health, a web-based PRO research program

Biogen Idec and Elan Corporation, plc, in collaboration with EPI-Q, Inc. and Avatar International, LLC, today announced the launch of My MS Health, a first-of-its-kind, web-based, patient-reported outcomes research program. My MS Health is designed to track and provide instant reports on patient function and quality of life using validated measures over time.

9 Jun 2010

NexGen Biomedical offers RNAi / PSR platform technology for sale

NexGen Biomedical, Inc. announced today that it is offering its RNAi / PSR platform technology for sale. "While technologies like siRNA are well suited for disease conditions involving expression of a single protein, the RNAi / PSR technology is better suited for conditions involving expression of a broad spectrum of proteins such as happens with cell hyperproliferation, inflammation, and viral infections.

8 Jun 2010

Idera reports preliminary results from IMO-3100 Phase 1 clinical trial for autoimmune, inflammatory diseases

Idera Pharmaceuticals, Inc. today announced preliminary results from a Phase 1 clinical trial of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for potential applications in autoimmune and inflammatory diseases. In this trial, healthy subjects in five dosage cohorts received single doses of IMO-3100 from 0.04 to 0.64 mg/kg. IMO-3100 was well tolerated at all dose levels.

8 Jun 2010

$UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study$

UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study

A new study shows that umbilical cord mesenchymal stem cell transplant may improve symptoms and biochemical values in patients with severe refractory systemic lupus erythematosus.

8 Jun 2010

Boosting levels of ABCG1 protein in diabetics will improve insulin production

If you think of diabetes onset like an elaborate molecular drama, then a research team led by a La Jolla Institute scientist has unmasked a previously unknown cellular player, which is critical to proper insulin secretion. "Defective insulin secretion is a hallmark of both type 1 and type 2 diabetes," said Catherine Hedrick, Ph.D., a scientist at the La Jolla Institute for Allergy & Immunology, who led the team, which included researchers from the University of Virginia.

8 Jun 2010

Vitiligo associated with genes variations linked to body's immune response

Scientists including researchers from the University of Florida have discovered additional evidence that generalized vitiligo - a disease that typically causes patches of white skin on the face, neck and extremities that pop star Michael Jackson may have experienced - is associated with slight variations in genes that play a role in the body's natural defenses.

8 Jun 2010

$Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer$

Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer

Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer. A total of 68 patients were enrolled with platinum-resistant disease, half of whom were platinum refractory. All 68 patients were evaluable for the primary endpoint of objective response rate using Gynecologic Cancer InterGroup criteria, which is a combination of response by tumor imaging (RECIST) and/or ovarian cancer biomarker (CA-125) criteria.

8 Jun 2010

Arthritis News and Research

Latest Arthritis News and Research

Study confirms impact of febrile neutropenia on chemotherapy delivery in NHL

Chiasma successfully completes Phase I clinical study of Octreolin

Emerging science of epigenetics offers new insights at crossroads of genes and the environment: Article

2010 GAPS sheds light on the painful reality of what life is like for gout patients

Baylor Institute of Immunology Research receives nearly $35M as grants in 2009

Human Genome Sciences submits BLA for BENLYSTA to FDA

Preclinical data of VB-201 to be presented at EULAR Annual European Congress of Rheumatology

DermaGenoma releases CelluliteDX Genetic Test for women

Therapies for female sexual dysfunction

Positive initial results from Nektar Therapeutics' NKTR-102 Phase 2 study for metastatic breast cancer

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

Update on Phase II clinical study of CH-4051 in rheumatoid arthritis

Some commonly used drugs cause bone loss: New research

Biogen, Elan launch My MS Health, a web-based PRO research program

NexGen Biomedical offers RNAi / PSR platform technology for sale

Idera reports preliminary results from IMO-3100 Phase 1 clinical trial for autoimmune, inflammatory diseases

UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study

Boosting levels of ABCG1 protein in diabetics will improve insulin production

Vitiligo associated with genes variations linked to body's immune response

Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Arthritis News and Research

Latest Arthritis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in